Batavia Biosciences is a contract development and manufacturing organization with expertise in viral vaccines, virotherapy, proteins and antibodies. We are not your standard CDMO – our customers regularly refer to us as their product development partner and thought partner.
How Batavia helps to reduce human suffering from infectious diseases and cancer
We accelerate the journey to the clinic by improving product yields, reducing process development time and increasing product stability. Our services and technologies have demonstrated to reduce risks, improve timelines and reduce costs in biopharmaceutical development to ensure the product reaches the patient without any unnecessary delays.
100
experts with industry experience
500
projects successfully completed
97
successful runs under GMP
70
returning customers
Latest resources from learning center
Date: 28 - 30 March 2022 Location: Basel, Switzerland Contact: Pieter-Jan Vos Are your joining us at the BIO Europe Spring event? Our team looks forward to meeting you in…
Leiden, April 15, 2020 – Immutep and Batavia Biosciences announce today that they have successfully generated a high yielding cell line for an IgG4-based antibody for LAG-3 immunotherapy for autoimmune…
Saint-Herblain, France, and Leiden, Netherlands, June 15, 2020 – Batavia Biosciences (“Batavia”) and Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”) today announced that they have entered into…
Batavia Biosciences is proud to announce that CJ CheilJedang (Seoul, South Korea) has selected the company to advance its position in the red biotechnology field. In a press release today,…
Talk to our experts
